Cited by 2,003Bone health and osteoporosis researchBone health and treatmentsHip and Femur Fractures

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture

Open access

Lyles, Kenneth W., Colón-Emeric, Cathleen S., Magaziner, Jay S., Adachi, Jonathan D., Pieper, Carl F., Mautalen, Carlos, Hyldstrup, Lars, Recknor, Chris, Nordsletten, Lars, Moore, Kathy A., Lavecchia, Catherine, Zhang, Jie, Mesenbrink, Peter, Hodgson, Patricia K., Abrams, Ken, Orloff, John J., Horowitz, Zebulun, Eriksen, Erik Fink, Boonen, Steven·2007·New England Journal of Medicine

DOI 10.1056/nejmoa074941PMC PMC2324066

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Mortality is increased after a hip fracture, and strategies that improve outcomes are needed. METHODS: In this randomized, double-blind, placebo-controlled trial, 1065 patients were assigned to receive yearly intravenous zoledronic acid (at a dose of 5 mg), and 1062 patients were assigned to receive placebo. The infusions were first administered within 90 days after surgical repair of a hip fracture. All patients (mean age, 74.5 years) received supplemental vitamin D and calcium. The median follow-up was 1.9 years. The primary end point was a new clinical fracture. RESULTS: The rates of any new clinical fracture were 8.6% in the zoledronic acid group and 13.9% in the placebo group, a 35% risk reduction with zoledronic acid (P=0.001); the respective rates of a new clinical vertebral fracture were 1.7% and 3.8% (P=0.02), and the respective rates of new nonvertebral fractures were 7.6% and 10.7% (P=0.03). In the safety analysis, 101 of 1054 patients in the zoledronic acid group (9.6%) and 141 of 1057 patients in the placebo group (13.3%) died, a reduction of 28% in deaths from any cause in the zoledronic acid group (P=0.01). The most frequent adverse events in patients receiving zoledronic acid were pyrexia, myalgia, and bone and musculoskeletal pain. No cases of osteonecrosis of the jaw were reported, and no adverse effects on the healing of fractures were noted. The rates of renal and cardiovascular adverse events, including atrial fibrillation and stroke, were similar in the two groups. CONCLUSIONS: An annual infusion of zoledronic acid within 90 days after repair of a low-trauma hip fracture was associated with a reduction in the rate of new clinical fractures and with improved survival. (ClinicalTrials.gov number, NCT00046254 [ClinicalTrials.gov].).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa074941

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Vitamin D Deficiency
Holick, M. F. (2007) · New England Journal of Medicine · doi:10.1056/nejmra070553 · Cited by 13,720
Vertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Hip fractures in the elderly: A world-wide projection
Cooper, C. C., Campion, G., & Melton, L. J. (1992) · Osteoporosis International · doi:10.1007/bf01623184 · Cited by 3,225
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986
Self-citation
Effect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
The Medical Dictionary for Regulatory Activities (MedDRA)
Brown, E. G., Wood, L., & Wood, S. (1999) · Drug Safety · doi:10.2165/00002018-199920020-00002 · Cited by 1,396
Medical Expenditures for the Treatment of Osteoporotic Fractures in the United States in 1995: Report from the National Osteoporosis Foundation
Ray, N. F., Chan, J. K., Thamer, M., & Melton, L. J. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.1.24 · Cited by 1,281

Show all 35 references

Research works printed but not linked: 2

Davidson CW, 2001, N Z Med J, 114, 329
2003, World Health Organ Tech Rep Ser, 921, 1

Sorted by citations

Items 501–600 of 1,000

The Interaction of Acute-Phase Reaction and Efficacy for Osteoporosis After Zoledronic Acid: HORIZON Pivotal Fracture Trial
Black, D. M., Reid, I. R., Napoli, N., Ewing, S. K., Shiraki, M., Nakamura, T., Takeuchi, Y., Schafer, A. L., Kim, T. Y., & Cauley, J. A. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4434 · Cited by 39
Mortality after hip fracture with vertebral compression fracture is poor
Imai, N., Endo, N., Hoshino, T., Suda, K., Miyasaka, D., & Ito, T. (2014) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-014-0640-4 · Cited by 39
Recent Advances in Osteoporosis Therapeutics
Sølling, A. S., Langdahl, B. L., & Cosman, F. (2025) · Annual Review of Medicine · doi:10.1146/annurev-med-050124-040555 · Cited by 42
Bisphosphonate use and hip fracture epidemiology: ecologic proof from the contrary
Fisher, A. A. (2010) · Clinical Interventions in Aging · doi:10.2147/cia.s13909 · Cited by 38
Effects of alendronate on bone formation and osteoclastic resorption after implantation of beta‐tricalcium phosphate
Tanaka, T., Saito, M., Chazono, M., Kumagae, Y., Kikuchi, T., Kitasato, S., & Marumo, K. (2009) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.32560 · Cited by 38
The effect of treatments for osteoporosis on mortality
Grey, A. B., & Bolland, M. J. (2012) · Osteoporosis International · doi:10.1007/s00198-012-2176-6 · Cited by 38
Sclerostin monoclonal antibody therapy with AMG 785: a potential treatment for osteoporosis
Lewiecki, E. M. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.540565 · Cited by 38
Mortality risk reduction differs according to bisphosphonate class: a 15-year observational study
Bliuc, D., Tran, T. S., van Geel, T. A. C. M., Adachi, J. D., Berger, C., van den Bergh, J. P., Eisman, J. A., Geusens, P., Goltzman, D., Hanley, D. A., et al. (2019) · Osteoporosis International · doi:10.1007/s00198-018-4806-0 · Cited by 38
Self-citation
Ten Years of Very Infrequent Zoledronate Therapy in Older Women: An Open-Label Extension of a Randomized Trial
Grey, A. B., Horne, A. M., Gamble, G. D., Mihov, B., Reid, I. R., & Bolland, M. J. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa062 · Cited by 38
Osteoporotic Vertebral Fractures are Common in Hip Fracture Patients and are Under-recognized
Kelly, M. A., McCabe, E., Bergin, D., Kearns, S. R., McCabe, J. P., Armstrong, C., Heaney, F., & CAREY, J. J. (2020) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2020.05.007 · Cited by 38
Benefits of Bisphosphonate Therapy: Beyond the Skeleton
Billington, E. O., & Reid, I. R. (2020) · Current Osteoporosis Reports · doi:10.1007/s11914-020-00612-4 · Cited by 38
Therapeutic Dimensions of Bisphosphonates: A Clinical Update
Vannala, V., Palaian, S., & Shankar, P. R. (2020) · International Journal of Preventive Medicine · doi:10.4103/ijpvm.ijpvm_33_19 · Cited by 38
Bisphosphonate nephropathy: A case series and review of the literature
van Zuijdewijn, C. L. M. D. R., van Dorp, W., Florquin, S., Roelofs, J. J. T. H., & Verburgh, K. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14780 · Cited by 38
Cardiovascular Effects of Noncardiovascular Drugs
Raj, S. R., Stein, C. M., Saavedra, P. J., & Roden, D. M. (2009) · Circulation · doi:10.1161/circulationaha.107.728576 · Cited by 38
Activation of p38 MAPK-regulated Bcl-xL signaling increases survival against zoledronic acid-induced apoptosis in osteoclast precursors
Tai, T., Su, F., Chen, C., Jou, I., & Lin, C. (2014) · Bone · doi:10.1016/j.bone.2014.07.003 · Cited by 38
Controversies Surrounding Vitamin D: Focus on Supplementation and Cancer
Minisola, S., Ferrone, F., Danese, V. C., Cecchetti, V., Pepe, J., Cipriani, C., & Colangelo, L. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16020189 · Cited by 37
Geriatric nutritional risk index as the prognostic factor in older patients with fragility hip fractures
Tsutsui, T., Fujiwara, T., Matsumoto, Y., Kimura, A., Kanahori, M., Arisumi, S., Oyamada, A., Ohishi, M., Ikuta, K., Tsuchiya, K., et al. (2023) · Osteoporosis International · doi:10.1007/s00198-023-06753-3 · Cited by 37
Fracture risk and adjuvant hormonal therapy among a population-based cohort of older female breast cancer patients
Neuner, J. M., Yen, T. W. F., Sparapani, R., Laud, P. W., & Nattinger, A. B. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1493-x · Cited by 38
Bisphosphonates and risk of atrial fibrillation: a meta-analysis
Kim, S. C., Kim, M. J., Cadarette, S. M., & Solomon, D. H. (2010) · Arthritis Research & Therapy · doi:10.1186/ar2938 · Cited by 37
Safety of drugs used in the treatment of osteoporosis
McGreevy, C., & Williams, D. J. (2011) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098611411012 · Cited by 37
Osteoporosis in men.
Rao, S., Budhwar, N., & Ashfaque, A. (2010) · PubMed · Cited by 37
Bone health in ageing men
David, K., Narinx, N., Antonio, L., Evenepoel, P., Claessens, F., Decallonne, B., & Vanderschueren, D. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-022-09738-5 · Cited by 37
Clinical role of bisphosphonate therapy
Fogelman, I., & Hampson (2012) · International Journal of Women s Health · doi:10.2147/ijwh.s24783 · Cited by 37
2011 Up-Date of the Consensus Statement of the Spanish Society of Rheumatology on Osteoporosis
Pérez-Edo, L., Ruiz, A. A., Vilaseca, D. R., García-Vadillo, A., Gay, N. G., Peris, P., Eslava, A. T., Audera, C. B., Aresté, J. F., Rodríguez, L. M. A., et al. (2011) · Reumatología Clínica (English Edition) · doi:10.1016/j.reumae.2011.05.007 · Cited by 36
Ibandronate does not increase risk of atrial fibrillation in analysis of pivotal clinical trials
Lewiecki, E. M., Cooper, C. C., Thompson, E., Hartl, F., Mehta, D., & Papapoulos, S. E. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02335.x · Cited by 36
Individualized fracture risk assessment: State-of-the-art and room for improvement
Nguyen, T. V. (2018) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2018.03.001 · Cited by 36
Postacute Management of Older Adults Suffering an Osteoporotic Hip Fracture: A Consensus Statement From the International Geriatric Fracture Society
Reyes, B. J., Mendelson, D. A., Mujahid, N., Mears, S. C., Gleason, L. J., Mangione, K. K., Nana, A., Mijares, M. C., & Ouslander, J. G. (2020) · Geriatric Orthopaedic Surgery & Rehabilitation · doi:10.1177/2151459320935100 · Cited by 38
Updated Recommendations for the Diagnosis and Management of Osteoporosis: A Local Perspective
Raef, H., Al-Bugami, M., Balhareth, S. S., Moawad, M. A., El-Shaker, M., Hussain, A. N., Al-Shaikh, A., & Al-Badawi, I. A. (2011) · Annals of Saudi Medicine · doi:10.4103/0256-4947.77502 · Cited by 36
Post-fracture management of patients with hip fracture: a perspective
Bruyère, O., Brandi, M. L., Burlet, N., Harvey, N. C., Lyritis, G. P., Minne, H. W., Boonen, S., Reginster, J.-Y., Rizzoli, R., & Åkesson, K. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802381430 · Cited by 36
Self-citation
Risk of Atrial Fibrillation Associated with Use of Bisphosphonates and Other Drugs Against Osteoporosis: A Cohort Study
Vestergaard, P., Schwartz, K., Pinholt, E. M., Rejnmark, L., & Mosekilde, L. (2010) · Calcified Tissue International · doi:10.1007/s00223-010-9349-0 · Cited by 35
Mortality following benign sacral insufficiency fracture and associated risk factors
Park, J.-W., Park, S., Lee, H. J., Lee, C., Chang, B., & Kim, H. (2017) · Archives of Osteoporosis · doi:10.1007/s11657-017-0395-3 · Cited by 35
Assessment and management of bone health in women with oestrogen receptor‐positive breast cancer receiving endocrine therapy: Position statement of the Endocrine Society of Australia, the Australian and New Zealand Bone & Mineral Society, the Australasian Menopause Society and the Clinical Oncology Society of Australia
Grossmann, M., Ramchand, S. K., Milat, F., Vincent, A. J., Lim, E., Kotowicz, M. A., Hicks, J., & Teede, H. J. (2018) · Clinical Endocrinology · doi:10.1111/cen.13735 · Cited by 35
Efficacy and efficiency of fracture liaison services to reduce the risk of recurrent osteoporotic fractures
Javaid, M. K. (2021) · Aging Clinical and Experimental Research · doi:10.1007/s40520-021-01844-9 · Cited by 35
Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene
Ko, S. S., & Jordan, V. C. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.557360 · Cited by 35
Retracted
Osteomalacia: The Missing Link in the Pathogenesis of Bisphosphonate-Related Osteonecrosis of the Jaws?
Bedogni, A., Saia, G., Bettini, G., Tronchet, A., Totola, A., Bedogni, G., Tregnago, P., Valenti, M. T., Bertoldo, F., Ferronato, G., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2012-0141 · Cited by 35
Osteoporosis in Men: Epidemiology, Pathophysiology, and Clinical Characterization
ORWOLL, E. S., & KLEIN, R. F. (2008) · Elsevier eBooks · doi:10.1016/b978-012370544-0.50044-6 · Cited by 35
In vitro and in vivo effects of zoledronic acid on senescence and senescence-associated secretory phenotype markers
Samakkarnthai, P., Saul, D., Zhang, L., Aversa, Z., Doolittle, M. L., Sfeir, J. G., Kaur, J., Atkinson, E. J., Edwards, J. R., Russell, G. G., et al. (2023) · Aging · doi:10.18632/aging.204701 · Cited by 34
The relationship between treatment-related changes in total hip BMD measured after 12, 18, and 24 mo and fracture risk reduction in osteoporosis clinical trials: the FNIH-ASBMR-SABRE project
Vilaça, T., Schini, M., Lui, L., Ewing, S. K., Thompson, A. R., Vittinghoff, E., Bauer, D. C., Eastell, R., Black, D. M., & Bouxsein, M. (2024) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjae126 · Cited by 35
Bisphosphonates for postmenopausal osteoporosis: Determining duration of treatment
Geusens, P. (2009) · Current Osteoporosis Reports · doi:10.1007/s11914-009-0003-6 · Cited by 34
Bisphosphonates in the management of thalassemia-associated osteoporosis: a systematic review of randomised controlled trials
Giusti, A. (2014) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-014-0584-8 · Cited by 34
Priming Primary Care Physicians to Treat Osteoporosis After a Fragility Fracture: An Integrated Multidisciplinary Approach
Roux, S., Beaulieu, M., Beaulieu, M., Cabana, F., & Boire, G. (2013) · The Journal of Rheumatology · doi:10.3899/jrheum.120908 · Cited by 34
Pharmacological diversity among drugs that inhibit bone resorption
Russell, R. G. G. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.05.005 · Cited by 36
Orthogeriatric co-management for the care of older subjects with hip fracture: recommendations from an Italian intersociety consensus
Vincentis, A. D., Behr, A. U., Bellelli, G., Bravi, M., Castaldo, A., Galluzzo, L., Iolascon, G., Maggi, S., Martini, E., Momoli, A., et al. (2021) · Aging Clinical and Experimental Research · doi:10.1007/s40520-021-01898-9 · Cited by 34
Bone Mineral Density and Bone Turnover 10 Years After a Single 5 mg Dose or Two 5-Yearly Lower Doses of Zoledronate in Osteopenic Older Women: An Open-Label Extension of a Randomized Controlled Trial
Grey, A. B., Bolland, M. J., Horne, A. M., Mihov, B., Gamble, G. D., & Reid, I. R. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4453 · Cited by 34
Male osteoporosis: new insights in an understudied disease
Haney, E. M., & Bliziotes, M. M. (2008) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e3283025eb0 · Cited by 34
Risks and benefits of long-term bisphosphonate therapy
Schmidt, G. A., Horner, K. E., McDanel, D. L., Ross, M. B., & Moores, K. G. (2010) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp090506 · Cited by 35
Screening for Osteoporosis: Systematic Review to Update the 2002 U.S. Preventive Services Task Force Recommendation
Hd, N., Em, H., Chou, R., Dana, T., Fu, R., & Bougatsos, C. (2010) · Europe PMC (PubMed Central) · Cited by 34
Nanotechnology Treatment Options for Osteoporosis and Its Corresponding Consequences
Wei, D., Jung, J., Yang, H., Stout, D., & Yang, L. (2016) · Current Osteoporosis Reports · doi:10.1007/s11914-016-0324-1 · Cited by 34
An initial loading-dose vitamin D versus placebo after hip fracture surgery: randomized trial
Mak, J. C. S., Mason, R. S., Klein, L., & Cameron, I. D. (2016) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-016-1174-9 · Cited by 34
New and developing pharmacotherapy for osteoporosis in men
Gennari, L., & Bilezikian, J. P. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1428559 · Cited by 34
Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis
Roux, C., Reid, D. M., Devogelaer, J. P., Saag, K. G., Lau, C. S., Reginster, J.-Y., Papanastasiou, P., Bucci-Rechtweg, C. M., Su, G., & Sambrook, P. N. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1800-1 · Cited by 35
Cardiovascular disease and bone
Eastell, R., Newman, C., & Crossman, D. C. (2010) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2010.06.008 · Cited by 33
Surgeons save bones: an algorithm for orthopedic surgeons managing secondary fracture prevention
Gosch, M., Kammerlander, C., Roth, T., Doshi, H. K., Gasser, R. W., & Blauth, M. (2013) · Archives of Orthopaedic and Trauma Surgery · doi:10.1007/s00402-013-1774-x · Cited by 33
Study of Adverse Effect Profile of Parenteral Zoledronic Acid in Female Patients with Osteoporosis
Kotian, P. (2016) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2016/17061.7021 · Cited by 33
Osteoporosis in the Women's Health Initiative: Another Treatment Gap?
Sattari, M., Cauley, J. A., GARVAN, C. W., Johnson, K., LaMonte, M. J., Li, W., Limacher, M. C., Manini, T. M., Sarto, G. E., Sullivan, S. D., et al. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.02.042 · Cited by 34
Anti‐Osteoporosis Medications Associated with Decreased Mortality after Hip Fracture
Wang, P., Li, Y., Zhuang, H., Yu, H., Cai, S., Xu, H. Y., Chen, Z., Lin, J., & Yao, X. (2019) · Orthopaedic Surgery · doi:10.1111/os.12517 · Cited by 33
Treatment Effects of Bisphosphonates and Denosumab on Survival and Refracture from Real-World Data of Hip-Fractured Patients
Behanová, M., Reichardt, B., Stamm, T., Zwerina, J., Klaus Klaushofer, A., & Kocijan, R. (2019) · Calcified Tissue International · doi:10.1007/s00223-019-00611-3 · Cited by 33
Adherence to anti-osteoporosis medication associated with lower mortality following hip fracture in older adults: a nationwide propensity score-matched cohort study
Yu, S., Cheng, J., Chen, Y., Chen, J., Hsu, C., Lai, H., Ko, C., Chiu, W.-C., Su, Y., & Cheng, T. (2019) · BMC Geriatrics · doi:10.1186/s12877-019-1278-9 · Cited by 33
Treatment of bone loss in proximal femurs of postmenopausal osteoporotic women with AGN1 local osteo-enhancement procedure (LOEP) increases hip bone mineral density and hip strength: a long-term prospective cohort study
Howe, J. G., Hill, R. S., Stroncek, J. D., Shaul, J. L., Favell, D., Cheng, R., Engelke, K., Genant, H. K., Lee, D. C., Keaveny, T. M., et al. (2019) · Osteoporosis International · doi:10.1007/s00198-019-05230-0 · Cited by 34
The diagnostic threshold for osteoporosis impedes fracture prevention in women at high risk for fracture: A registry-based cohort study
Leslie, W. D., Seeman, E., Morin, S. N., Lix, L. M., & Majumdar, S. R. (2018) · Bone · doi:10.1016/j.bone.2018.07.004 · Cited by 33
Follow-up Bone Mineral Density Testing: 2023 Official Positions of the International Society for Clinical Densitometry
Gani, L. U., Sritara, C., Blank, R. D., Chen, W., Gilmour, J., Dhaliwal, R., & Gill, R. S. (2023) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2023.101440 · Cited by 34
Life Expectancy in Patients Treated for Osteoporosis: Observational Cohort Study Using National Danish Prescription Data
Abrahamsen, B., Osmond, C., & Cooper, C. C. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2478 · Cited by 32
Safety of Bisphosphonates
Orozco, C., & Maalouf, N. M. (2012) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2012.09.001 · Cited by 33
The Use of Zoledronic Acid in Men Receiving Androgen Deprivation Therapy for Prostate Cancer With Severe Osteopenia or Osteoporosis
Campbell, S. C., Bhoopalam, N., MORITZ, T. E., Pandya, M., Iyer, P., VanVeldhuizen, P. J., Ellis, N. K., Thottapurathu, L., Garewal, H. S., Warren, S. R., et al. (2010) · Urology · doi:10.1016/j.urology.2009.11.083 · Cited by 32
Osteoporosis treatment: Focus on safety
Reid, I. R. (2013) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2013.03.012 · Cited by 32
A highly sensitive prenylation assay revealsin vivoeffects of bisphosphonate drug on the Rab prenylome of macrophages outside the skeleton
Ali, N., Jurczyluk, J., Shay, G., Tnimov, Z., Alexandrov, K. A., Munoz, M. A., Skinner, O. P., Pavlos, N. J., & Rogers, M. J. (2015) · Small GTPases · doi:10.1080/21541248.2015.1085485 · Cited by 32
Current role for bone absorptiometry
Roux, C., & Briot, K. (2016) · Joint Bone Spine · doi:10.1016/j.jbspin.2016.02.032 · Cited by 32
The why and how of sequential and combination therapy in osteoporosis. A review of the current evidence
Chandran, M. (2022) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000564 · Cited by 34
Fracture prevention in patients with cognitive impairment presenting with a hip fracture: secondary analysis of data from the HORIZON Recurrent Fracture Trial
Prieto‐Alhambra, D., Judge, A., Arden, N. K., Cooper, C. C., Lyles, K. W., & Javaid, M. K. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2420-8 · Cited by 33
Self-citation
Pemphigus and Osteoporosis
Wohl, Y., Dreiher, J., & Cohen, A. D. (2010) · Archives of Dermatology · doi:10.1001/archdermatol.2010.257 · Cited by 32
Idiopathic Osteoporosis in Men
Gennari, L., & Bilezikian, J. P. (2013) · Current Osteoporosis Reports · doi:10.1007/s11914-013-0164-1 · Cited by 32
Beneficial effect of risedronate for preventing recurrent hip fracture in the elderly Japanese women
Osaki, M., Tatsuki, K., Hashikawa, T., Norimatsu, T., Chiba, K., Motokawa, S., Furuichi, I., Doiguchi, Y., Aoyagi, K., & Shindo, H. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1556-7 · Cited by 32
Prevention of osteoporosis-related fractures among postmenopausal women and older men
Rahmani, P., & Morin, S. N. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.080709 · Cited by 32
Bisphosphonates and mortality: confounding in observational studies?
Bergman, J., Nordström, A., Hommel, A., Kivipelto, M., & Nordström, P. (2019) · Osteoporosis International · doi:10.1007/s00198-019-05097-1 · Cited by 33
Treatment of Osteoporosis and Prevention of New Fractures: Role of Intravenously Administered Bisphosphonates
Cosman, F. (2009) · Endocrine Practice · doi:10.4158/ep08306.orr1 · Cited by 32
Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study
Everts‐Graber, J., Bonél, H., Lehmann, D., Gahl, B., Häuselmann, H., Studer, U., Ziswiler, H., Reichenbach, S., & Lehmann, T. (2023) · Osteoporosis International · doi:10.1007/s00198-023-06863-y · Cited by 32
Romosozumab for the treatment of osteoporosis – a systematic review
Mäkinen, V.-N., Sølling, A. S., McClung, M. R., & Langdahl, B. L. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02469-1 · Cited by 32
New developments in the treatment of osteoporosis
Eriksen, E. F., Halse, J., & Moen, M. H. (2012) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/j.1600-0412.2012.01473.x · Cited by 32
Self-citation
The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis
Hwang, J., Chin, L.-S., Chen, J., Yang, T., Chen, P.-Q., Tsai, K., & Leung, P. (2010) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-010-0223-y · Cited by 31
Depression is associated with increased incidence of osteoporotic thoracolumbar fracture in postmenopausal women: a prospective study
Zong, Y., Tang, Y., Xue, Y., Ding, H., Li, Z., He, D., Zhao, Y., & Wang, P. (2015) · European Spine Journal · doi:10.1007/s00586-015-4033-8 · Cited by 32
Osteoporosis Treatment After Hip Fracture
Bauer, D. C. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.0844 · Cited by 31
Management of comorbidities in haemophilia
Kempton, C. L., Makris, M., & Holme, P. A. (2020) · Haemophilia · doi:10.1111/hae.14013 · Cited by 31
Management of osteoporosis in older men
Kaufman, J. (2021) · Aging Clinical and Experimental Research · doi:10.1007/s40520-021-01845-8 · Cited by 31
PHARMACOLOGICAL MANAGEMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN: THE CURRENT STATE OF THE ART
Gatti, D., & Fassio, A. (2019) · Journal of Population Therapeutics and Clinical Pharmacology · doi:10.15586/jptcp.v26i4.646 · Cited by 31
The cost effectiveness of zoledronic acid 5 mg for the management of postmenopausal osteoporosis in women with prior fractures: evidence from Finland, Norway and the Netherlands
Akehurst, R. L., Brereton, N. J., Ariely, R., Lusa, T., Groot, M. D., Foss, P., & Boonen, S. (2011) · Journal of Medical Economics · doi:10.3111/13696998.2010.545563 · Cited by 31
Self-citation
Fragility fracture prevention: review from a Japanese perspective.
Hagino, H. (2012) · Europe PMC (PubMed Central) · Cited by 31
A perspective on male osteoporosis
Binkley, N. (2009) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2009.10.001 · Cited by 31
Minodronate for the treatment of osteoporosis
Ohishi, T., & Matsuyama, Y. (2018) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s149236 · Cited by 32
Zoledronic Acid
Deeks, E. D., & Perry, C. M. (2008) · Drugs & Aging · doi:10.2165/0002512-200825110-00007 · Cited by 31
Discrepancies in predicted fracture risk in elderly people
Bolland, M. J., Jackson, R., Gamble, G. D., & Grey, A. B. (2013) · BMJ · doi:10.1136/bmj.e8669 · Cited by 30
Reduced Bone Loss Is Associated With Reduced Mortality Risk in Subjects Exposed to Nitrogen Bisphosphonates: A Mediation Analysis
Bliuc, D., Tran, T. S., van Geel, T. A. C. M., Adachi, J. D., Berger, C., van den Bergh, J. P., Eisman, J. A., Geusens, P., Goltzman, D., Hanley, D. A., et al. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3816 · Cited by 30
Self-citation
The use of 2-, 5-, and 10-year probabilities to characterize fracture risk after a recent sentinel fracture
Kanis, J. А., Johansson, H., Harvey, N. C., Gudnason, V. G., Sigurðsson, G., Siggeirsdóttir, K., Lorentzon, M., Liu, E., Vandenput, L., Leslie, W. D., et al. (2020) · Osteoporosis International · doi:10.1007/s00198-020-05700-w · Cited by 30
Osteonecrosis de los maxilares: Documento de consenso
Henríquez, M. S., Romero, M. G. D. T., Jv, B. S., Díaz Curiel, M., Díez Pérez, A., Jódar Gimeno, E., Junquera Gutiérrez, L., Del Pino Montes, J., Barrero, M. V., Científico, M. D. C., et al. (2009) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 30
Osteoporosis Diagnosis, Management, and Referral Practice After Fragility Fractures
Snodgrass, P., Zou, A., Gruntmanis, U., & Gitajn, I. L. (2022) · Current Osteoporosis Reports · doi:10.1007/s11914-022-00730-1 · Cited by 30
Cardiovascular diseases in older patients with osteoporotic hip fracture: prevalence, disturbances in mineral and bone metabolism, and bidirectional links
Fisher, A. A., Srikusalanukul, W., Davis, & Smith (2013) · Clinical Interventions in Aging · doi:10.2147/cia.s38856 · Cited by 30
Ortogeriatría en pacientes agudos (II). Aspectos clínicos
González-Montalvo, J. I., Alarcón, T., Rodil, B. P., Gotor, P., & Sierra, T. P. (2008) · Revista Española de Geriatría y Gerontología · doi:10.1016/s0211-139x(08)73574-1 · Cited by 30
Zoledronic acid results in better health-related quality of life following hip fracture: the HORIZON–Recurrent Fracture Trial
Adachi, J. D., Lyles, K. W., Colon-Emeric, C. S., Boonen, S., Pieper, C. F., Mautalén, C., Hyldstrup, L., Recknor, C. P., Nordsletten, L., Moore, K., et al. (2011) · Osteoporosis International · doi:10.1007/s00198-010-1514-9 · Cited by 30
Self-citation
Diagnosis and Treatment of Osteoporosis in Older Adults
Diab, D. L., & Watts, N. B. (2013) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.02.007 · Cited by 30
Osteoporosis in men: epidemiology and treatment with denosumab
Sutton, E., Sidlauskas, K., & Biddle, M. (2014) · Clinical Interventions in Aging · doi:10.2147/cia.s51940 · Cited by 30
Efficacy of bisphosphonates against osteoporosis in adult men: a meta-analysis of randomized controlled trials
Chen, L., Wang, G., Zheng, F., Zhao, H., & Li, H. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3148-4 · Cited by 31

Authors: Lyles, K. W., Colón-Emeric, C. S., Magaziner, J. S., Adachi, J. D., Pieper, C. F., Mautalen, C., Hyldstrup, L., Recknor, C., Nordsletten, L., Moore, K. A., Lavecchia, C., Zhang, J., Mesenbrink, P., Hodgson, P. K., Abrams, K., Orloff, J. J., Horowitz, Z., Eriksen, E. F., & Boonen, S.
Affiliations: Veterans Health Administration (US)
University of Maryland, Baltimore (US)
McMaster University (CA)
Duke Medical Center (US)
Hvidovre Hospital (DK)
Oslo University Hospital (NO)
Savient Pharmaceuticals (United States) (US)
Novartis (Switzerland) (CH)
KU Leuven (BE)
ORCID: Magaziner, Jay S.
Adachi, Jonathan D.
Pieper, Carl F.
Nordsletten, Lars
Zhang, Jie
Mesenbrink, Peter
Eriksen, Erik Fink
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2007-11
Volume: 357
Issue: 18
Pages: 1799-1809
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa074941
PMC: PMC2324066
OpenAlex: W2163830908
Cited by: 2,003
References: 35
Citations by year: 2026: 53 · 2025: 88 · 2024: 67 · 2023: 75 · 2022: 78 · 2021: 119 · 2020: 104 · 2019: 94 · 2018: 92 · 2017: 79 · 2016: 97 · 2015: 92 · 2014: 106 · 2013: 115 · 2012: 122
FWCI: 160.83
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
PubMed Central (acceptedVersion)
IRIS (submittedVersion)
SERVAL (Université de Lausanne) (submittedVersion)
Funders: Amgen
Eli Lilly and Company
Pfizer
GlaxoSmithKline
Sanofi
Savient Pharmaceuticals
Novo Nordisk
Servier
National Institute on Aging (K23AG024787)
Topics: Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
Health Sciences › Medicine › Oncology › Bone health and treatments
Health Sciences › Medicine › Surgery › Hip and Femur Fractures
Keywords: zoledronic acid, hip fracture, bisphosphonates, fracture prevention, vertebral fractures, non-vertebral fractures, mortality, postoperative treatment, osteoporosis, adverse events, osteonecrosis of the jaw
MeSH terms: Zoledronic Acid, Aged, Aged, 80 and over, Calcium, Diphosphonates, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Hip Fractures, Humans, Imidazoles, Infusions, Intravenous, Male, Middle Aged, Vitamin D, Bone Density, Survival Analysis, Bone Density Conservation Agents, Fractures, Bone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks